BAN2238 / BioArctic - LARVOL DELTA

BioArctic Interim Report for the period October - December 2025 (PRNewswire) - "In the fourth quarter, we also nominated candidate drugs in two projects, and they are now being prepared for clinical studies. One project in ALS, BAN3014, and one in Parkinson-related disorders, BAN2238, where the latter is a successor to exidavnemab and linked to our BrainTransporter. The Phase 2a study with exidavnemab in Parkinson's disease and multiple system atrophy is also progressing well. In 2026, we expect to complete the Phase 2a study and the planning for Phase 2b is in full swing."

New molecule • New P2b trial • Trial completion date • Multiple System Atrophy • Parkinson's Disease